-

Viz.ai Launches Viz 3D CTA™ to Deliver Enhanced Imaging and Accelerate Clinical Decision-Making

New feature provides AI-enhanced 3D imaging to improve neurovascular visualization and streamline workflows

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz 3D CTA, a new solution that automatically converts computed tomography angiography (CTA) scans into high-resolution, AI-enhanced 3D images for faster and clearer neurovascular visualization. Fully integrated into the Viz.ai platform, this capability enables care teams to interact with complex neurovascular anatomy in real-time — automatically removing bone and venous structures to enhance clarity and support time savings in stroke and aneurysm workflows.

“Viz 3D CTA gives me a clearer, faster view of what’s going on. Being able to rotate the image and see vessels from different angles makes a big difference, especially in tricky areas,” said Benjamin Alwood, MD, neurologist at UF Health Jacksonville. “It’s also a great safety net for spotting occlusions that might otherwise be missed. Having this kind of clarity right away helps me make quicker, more confident decisions.”

Viz 3D CTA addresses challenges in neurovascular imaging, including delays due to manual 3D renderings, limited spatial context in PACS, and difficulty viewing smaller or more distal vessel abnormalities. With automated post-processing, skull-stripped views, and interactive tools — including sagittal and axial rotation — Viz 3D CTA offers clinicians a dynamic, full-brain perspective within minutes.

“With Viz 3D CTA, we’re extending the Viz.ai One® platform with a powerful imaging tool that enables clearer, faster decisions in neurovascular care,” said Prem Batchu-Green, VP of Care Pathways, Value and Success at Viz.ai. “We are proud to bring this capability directly into the hands of providers who are working to save lives and preserve function every day.”

Viz 3D CTA is now available to hospitals and health systems on the Viz.ai One platform, which is deployed in over 1,700 hospitals and health systems. To learn more about Viz 3D CTA, visit viz.ai/neuro.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

Contacts

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Viz.ai, Inc.


Release Versions

Contacts

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Social Media Profiles
More News From Viz.ai, Inc.

Viz.ai and Salesforce Collaborate to Transform Pharma Engagement With Real-Time Clinical Intelligence for Agentforce

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new real-time clinical intelligence service for Salesforce’s Agentforce Life Sciences. These services will power new and existing agentic solutions for life sciences customers, including a data integration that will bring Viz.ai’s real-time data, triggers, and clinical intelligence layer from across a network of nearly 2,000 hospitals covering 230...

Viz.ai Closes 2025 with Record Scale and Patient Impact, Achieving Profitability in Its Healthcare Business while Accelerating Life Sciences Growth

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a milestone year marked by record growth in its provider footprint, profitability across its healthcare business, the launch of Viz Oncology and Viz Assist, and the doubling of its life sciences business over the past 18 months. Viz.ai is now adopted in nearly 2,000 hospitals across the United States, including the majority of the 50 largest health systems, suppo...

Viz.ai and NCCN Collaborate to Integrate NCCN Guidelines into Clinical Workflows for Oncologists

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration integrates NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Thr...
Back to Newsroom